- Home
- ORBS vs CYRX Comparison
ORBS vs CYRX Comparison
Compare ORBS & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORBS | CYRX |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.9M | 421.6M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | ORBS | CYRX |
|---|---|---|
| Price | $1.01 | $8.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.94 |
| AVG Volume (30 Days) | ★ 25.3M | 412.9K |
| Earning Date | 04-14-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $10.92 |
| Revenue Next Year | N/A | $8.08 |
| P/E Ratio | ★ N/A | $5.74 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $4.63 |
| 52 Week High | $15.96 | $11.45 |
Technical Indicators
Market Signals| Indicator | ORBS | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 46.49 |
| Support Level | $0.74 | $8.01 |
| Resistance Level | $1.29 | $8.45 |
| Average True Range (ATR) | 0.15 | 0.48 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 53.05 | 31.69 |
Price Performance
Historical ComparisonAbout ORBS Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.